Co-Authors
This is a "connection" page, showing publications co-authored by Laurent Kaiser and Idris Guessous.
Connection Strength
1.969
-
Detection of Spatiotemporal Clusters of COVID-19-Associated Symptoms and Prevention Using a Participatory Surveillance App: Protocol for the @choum Study. JMIR Res Protoc. 2021 Oct 06; 10(10):e30444.
Score: 0.243
-
Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nat Commun. 2021 06 08; 12(1):3455.
Score: 0.237
-
Socioeconomically Disadvantaged Neighborhoods Face Increased Persistence of SARS-CoV-2 Clusters. Front Public Health. 2020; 8:626090.
Score: 0.232
-
Geospatial digital monitoring of COVID-19 cases at high spatiotemporal resolution. Lancet Digit Health. 2020 08; 2(8):e393-e394.
Score: 0.222
-
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020 08 01; 396(10247):313-319.
Score: 0.222
-
SARS-CoV-2 infection as a trigger of humoral response against apolipoprotein A-1. Eur J Clin Invest. 2021 Nov; 51(11):e13661.
Score: 0.060
-
Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal Swabs. Front Med (Lausanne). 2021; 8:685124.
Score: 0.060
-
Persistence of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance. Clin Microbiol Infect. 2021 Nov; 27(11):1695.e7-1695.e12.
Score: 0.060
-
Development and validation of the OUTCoV score to predict the risk of hospitalisation among patients with SARS-CoV-2 infection in ambulatory settings: a prospective cohort study. BMJ Open. 2021 06 18; 11(6):e044242.
Score: 0.059
-
Insights into household transmission of SARS-CoV-2 from a population-based serological survey. Nat Commun. 2021 06 15; 12(1):3643.
Score: 0.059
-
Risk of reinfection after seroconversion to SARS-CoV-2: A population-based propensity-score matched cohort study. Clin Infect Dis. 2021 May 27.
Score: 0.059
-
SARS-CoV-2 testing strategy: A comparison of restricted and extended strategies in a Swiss outpatient cohort from the community and hospital employees. PLoS One. 2021; 16(4):e0250021.
Score: 0.059
-
Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings. J Clin Med. 2021 Apr 10; 10(8).
Score: 0.059
-
Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak. Lancet Infect Dis. 2021 05; 21(5):600-601.
Score: 0.058
-
Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial. BMJ Open. 2020 11 12; 10(11):e040110.
Score: 0.057
-
Diagnostic accuracy of Augurix COVID-19 IgG serology rapid test. Eur J Clin Invest. 2020 Oct; 50(10):e13357.
Score: 0.056
-
Head-to-Head Accuracy Comparison of Three Commercial COVID-19 IgM/IgG Serology Rapid Tests. J Clin Med. 2020 Jul 24; 9(8).
Score: 0.056
-
Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis. 2021 04; 21(4):e69-e70.
Score: 0.056
-
Validation of a commercially available SARS-CoV-2 serological immunoassay. Clin Microbiol Infect. 2020 Oct; 26(10):1386-1394.
Score: 0.056